180 related articles for article (PubMed ID: 20809642)
1. Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.
Trabocchi A; Menchi G; Cini N; Bianchini F; Raspanti S; Bottoncetti A; Pupi A; Calorini L; Guarna A
J Med Chem; 2010 Oct; 53(19):7119-28. PubMed ID: 20809642
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
3. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis.
Trikha M; Zhou Z; Timar J; Raso E; Kennel M; Emmell E; Nakada MT
Cancer Res; 2002 May; 62(10):2824-33. PubMed ID: 12019160
[TBL] [Abstract][Full Text] [Related]
4. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin.
Nam JO; Jeong HW; Lee BH; Park RW; Kim IS
Cancer Res; 2005 May; 65(10):4153-61. PubMed ID: 15899806
[TBL] [Abstract][Full Text] [Related]
5. Radiosynthesis and micro-SPECT analysis of triazole-based RGD integrin ligands as non-peptide molecular imaging probes for angiogenesis.
Bianchini F; Fabbrizzi P; Menchi G; Raspanti S; Bottoncetti A; Passeri A; Andreucci E; Guarna A; Calorini L; Pupi A; Trabocchi A
Bioorg Med Chem; 2015 Mar; 23(5):1112-22. PubMed ID: 25637121
[TBL] [Abstract][Full Text] [Related]
6. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
[TBL] [Abstract][Full Text] [Related]
7. Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity.
Cini N; Trabocchi A; Menchi G; Bottoncetti A; Raspanti S; Pupi A; Guarna A
Bioorg Med Chem; 2009 Feb; 17(4):1542-9. PubMed ID: 19195898
[TBL] [Abstract][Full Text] [Related]
8. Probing for integrin alpha v beta3 binding of RGD peptides using fluorescence polarization.
Wang W; Wu Q; Pasuelo M; McMurray JS; Li C
Bioconjug Chem; 2005; 16(3):729-34. PubMed ID: 15898744
[TBL] [Abstract][Full Text] [Related]
9. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo.
Silletti S; Kessler T; Goldberg J; Boger DL; Cheresh DA
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):119-24. PubMed ID: 11134507
[TBL] [Abstract][Full Text] [Related]
10. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
[TBL] [Abstract][Full Text] [Related]
11. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties.
Maeshima Y; Colorado PC; Kalluri R
J Biol Chem; 2000 Aug; 275(31):23745-50. PubMed ID: 10837460
[TBL] [Abstract][Full Text] [Related]
12. Cell surface proteolysis by serine proteinases enhances RGD-sensitive melanoma cell adhesion on fibrinogen and vitronectin.
Fujii K; Imamura S
Exp Cell Res; 1995 Sep; 220(1):201-11. PubMed ID: 7545129
[TBL] [Abstract][Full Text] [Related]
13. Insight to the binding mode of triazole RGD-peptidomimetics to integrin-rich cancer cells by NMR and molecular modeling.
Vasile F; Menchi G; Lenci E; Guarna A; Potenza D; Trabocchi A
Bioorg Med Chem; 2016 Mar; 24(5):989-94. PubMed ID: 26818999
[TBL] [Abstract][Full Text] [Related]
14. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo.
Trikha M; Zhou Z; Nemeth JA; Chen Q; Sharp C; Emmell E; Giles-Komar J; Nakada MT
Int J Cancer; 2004 Jun; 110(3):326-35. PubMed ID: 15095296
[TBL] [Abstract][Full Text] [Related]
15. ¹²⁵I-radiolabeled morpholine-containing arginine-glycine-aspartate (RGD) ligand of αvβ₃ integrin as a molecular imaging probe for angiogenesis.
Bianchini F; Cini N; Trabocchi A; Bottoncetti A; Raspanti S; Vanzi E; Menchi G; Guarna A; Pupi A; Calorini L
J Med Chem; 2012 Jun; 55(11):5024-33. PubMed ID: 22621422
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo effects of a cyclic peptide with affinity for the alpha(nu)beta3 integrin in human melanoma cells.
Allman R; Cowburn P; Mason M
Eur J Cancer; 2000 Feb; 36(3):410-22. PubMed ID: 10708944
[TBL] [Abstract][Full Text] [Related]
17. Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5).
Zannetti A; Del Vecchio S; Iommelli F; Del Gatto A; De Luca S; Zaccaro L; Papaccioli A; Sommella J; Panico M; Speranza A; Grieco P; Novellino E; Saviano M; Pedone C; Salvatore M
Clin Cancer Res; 2009 Aug; 15(16):5224-33. PubMed ID: 19671851
[TBL] [Abstract][Full Text] [Related]
18. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
[TBL] [Abstract][Full Text] [Related]
19. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
20. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay.
Wong A; Hwang SM; McDevitt P; McNulty D; Stadel JM; Johanson K
Mol Pharmacol; 1996 Sep; 50(3):529-37. PubMed ID: 8794891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
